Inclusion Criteria:

          -  Signed Informed Consent Age >18 years Histologically confirmed metastatic or advanced
             prostate cancer adenocarcinoma that has received no treatment for the castration
             resistant disease and has progressed during treatment with complete androgen blockade
             (luteinizing hormone releasing hormone agonist or antagonist and an antiandrogen eg.
             Bicalutamide).

        Availability of a representative formalin-fixed, paraffin-embedded tumor specimen (FFPE)
        that enabled definitive diagnosis of prostate cancer.

        Two rising PSA levels >2ng/ml measured 1 week apart during or following the most recent
        prior therapy for prostate cancer (PCWG2 criteria) or radiographic evidence of disease
        progression in bone with or without biochemical disease progression on the basis of the PSA
        value.

        Ongoing androgen deprivation, with serum testosterone <50ng/dl ECOG performance status 0-1
        at screening Adequate hematologic and organ function within 14 days before the first study
        treatment (hematologic parameters must be assessed >14 days after a prior transfusion, if
        any) as defined by

          -  Hemoglobin >9g/dl

          -  Neutrophils >1500/μL

          -  Platelet count >100000/μL

          -  Total bilirubin <1,5xULN with the following exception:

             o Patients with known Gilbert syndrome who have serum bilirubin<3xULN

          -  AST and ALT<2,5xULN with the following exception

             o Patients with bone-only metastasis may have AST<5xULN, provided that ALT <2,5xULN
             and total bilirubin <1,5xULN

          -  Serum albumin >3g/dl

          -  Serum potassium ≥3.5mmol/L

          -  Serum creatinine <1,5xULN or creatinine clearance of >50ml/min based on
             Cockcroft-Gault equation

          -  Agreement by patient and/or partner to use an effective form of contraception
             including surgical sterilization, reliable barrier method, birth control pills,
             contraceptive hormone implants or true abstinence and to continue its use for the
             duration of the study and for 6 months after the last dose of study treatment.

        Exclusion Criteria:

          -  Small cell or neuroendocrine prostate carcinoma Inability or unwillingness to swallow
             pills Malabsorption syndrome or other condition that would interfere with enteral
             absorption Congenital long QT syndrome or QTc>480msec NYHA Class II to IV heart
             failure or LVEF <50% or ventricular arrhythmia requiring medication Previous therapy
             for prostate cancer with CYP17 inhibitors including ketoconazole or investigational
             agents (VMT-VT-464, Orteronel etc) or novel antiandrogens (enzalutamide of OMD-208)
             for more than 7 days Presence of visceral metastasis History of another invasive
             cancer within 3 years from screening, with the exception of fully treated cancers with
             a remote probability of recurrence Duration of previous Androgen Deprivation Therapy
             <12months Active infection requiring IV antibiotics

        Clinically significant cardiovascular disease including the following:

          -  unstable angina,

          -  myocardial infarction within 6 months from screening, or

          -  cerebrovascular accident within 6 months from screening Major surgical procedure
             within 4 weeks prior to initiation of study treatment Treatment with an
             investigational agent within 4 weeks prior to initiation of study treatment
             Unresolved, clinical significant toxicity from prior treatment Hypersensitivity
             reaction to the active pharmaceutical ingredient or any of the tablet components Any
             medical condition that restrain the patient to comply with study and follow-up
             procedures Inability to comply with study and follow up procedures